Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents
  • Published:

Patenting race

Nature Biotechnology volume 24, pages 1349–1351 (2006)Cite this article

As genetic databases continue to yield new insights and inventions, the commercial incentive to conflate race and genetics may be hard to resist.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Duster, T. Science 307, 1050–1051 (2005).

    Article  CAS  Google Scholar 

  2. Editorial. Nat. Biotechnol. 23, 903 (2005).

  3. US Office of Management and Budget. Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity (October 30, 1997).

  4. US Patent No. 6,465,463.

  5. US Patent No. 4,868,179.

  6. Griffith, V. FDA backs ethnically targeted drug. Financial Times (March 9, 2001).

    Google Scholar 

  7. Taylor, A.L. et al. N. Engl. J. Med. 351, 2049–2057 (2004).

    Article  CAS  Google Scholar 

  8. Kahn, J. Yale J. Health Policy Law Ethics 4, 1–46 (2004).

    Google Scholar 

  9. Herper, M. Race-based medicine arrives. Forbes (May 10, 2005).

  10. Royal Society. Personalised Medicines: Hopes and Realities (Royal Society, London, 2005).

  11. Kienzlen, G. BRCA2 patent upheld. The Scientist (July 1, 2005).

    Google Scholar 

  12. Gessen, M. Jewish guinea pigs. Slate.com (July 26, 2005).

    Google Scholar 

  13. For example, the US National Institutes of Health Revitalization Act of 1993, (PL 103-43), which directed the NIH to establish guidelines for inclusion of women and minorities in clinical research; and the Food and Drug Modernization Act of 1997 (111 Stat. 2296), which, in the context of drug development, directed that “the Secretary [of Health and Human Services] shall, in consultation with the Director of the National Institutes of Health and with representatives of the drug manufacturing industry, review and develop guidance, as appropriate, on the inclusion of women and minorities in clinical trials.”

  14. US Food and Drug Administration. Guidance for Industry: Population Pharmacokinetics (February 1999).

  15. US Food and Drug Administration. Guidance for Industry: Collection of Race and Ethnicity Data in Clinical Trials (September, 2005).

Download references

Author information

Authors and Affiliations

  1. Hamline University School of Law, 1536 Hewitt Avenue, Saint Paul, 55104-1237, Minnesota, USA

    Jonathan Kahn

Authors
  1. Jonathan Kahn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kahn, J. Patenting race. Nat Biotechnol 24, 1349–1351 (2006). https://doi.org/10.1038/nbt1106-1349

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1106-1349

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing